会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 81. 发明授权
    • Vehicle front part structure
    • 车辆前部结构
    • US06382709B1
    • 2002-05-07
    • US09642624
    • 2000-08-18
    • Takashi ChirifuShirou YamamuroKoji Yamada
    • Takashi ChirifuShirou YamamuroKoji Yamada
    • B62D2508
    • B60R19/24B60R2019/182B62D21/152B62D25/082B62D25/084B62D29/008
    • A vehicle front part structure includes right and left front side frames provided rightwardly and leftwardly of and extending longitudinally of a vehicle body. A front bumper beam is attached to front ends of the right and left front side frames and extends transversely of the vehicle body. Right and left substays extend downwardly from front parts of the right and left front side frames. The right and left substays have lower parts connected to each other through a front lower cross member. Each of the right and left substays has first portions coupled through fastening members to and has second portions coupled through fillet welding to the respective front parts of the right and left front side frames.
    • 车辆前部结构包括左右前侧框架,其在车体的左右方向设置并向车身纵向延伸。 前保险杠梁连接在右前框架和左前框架的前端,横向于车身延伸。 右侧和左侧的底板从右侧和左侧框架的前部向下延伸。 右侧和左侧子站具有通过前部下部横向构件相互连接的下部部件。 每个左右和右侧分别具有通过紧固构件联接到第一部分,并且具有通过角焊焊接到左前侧框架和左前侧框架的相应前部部分的第二部分。
    • 82. 发明授权
    • Waveguide optical semiconductor device, method of fabricating the same and optical device module
    • 波导光半导体器件及其制造方法以及光器件模块
    • US06360048B1
    • 2002-03-19
    • US09434485
    • 1999-11-05
    • Koji Yamada
    • Koji Yamada
    • G02B610
    • G02F1/025G02B6/423G02F2201/066G02F2201/12H01S5/0224H01S5/02252H01S5/02268H01S5/0425H01S5/227H01S5/2275
    • A waveguide optical semiconductor device, a method of fabricating the same and an optical device module. The semiconductor device includes a substrate, a waveguide formed on the substrate, an electrode layer formed on the waveguide, and bumpers formed on the substrate. The bumpers are disposed on both side of the waveguide, and top surfaces of the bumpers are higher than a top surface of the electrode layer. The method of fabrication includes forming semiconductor layers for waveguide on a substrate, forming another semiconductor layer on the semiconductor layers, removing the another semiconductor layer and at least a part of the semiconductor layers selectively so that grooves are formed on both side of a region where the waveguide are expected to be formed, removing the another semiconductor layer at the region, remained portions of the another semiconductor layer form bumpers. The module includes a waveguide optical semiconductor device having bumpers disposed on both side of the waveguide, and a carrier having a mounting region in contact with the top surfaces of the bumpers.
    • 波导光半导体器件,其制造方法和光学器件模块。 半导体器件包括衬底,形成在衬底上的波导,形成在波导上的电极层和形成在衬底上的缓冲器。 缓冲器设置在波导的两侧,缓冲器的顶表面高于电极层的顶表面。 制造方法包括在衬底上形成用于波导的半导体层,在半导体层上形成另一个半导体层,选择性地去除另一半导体层和至少一部分半导体层,使得沟槽形成在 期望形成波导,去除该区域处的另一半导体层,保留另一半导体层的部分形成保险杠。 该模块包括具有布置在波导两侧的缓冲器的波导光学半导体器件和具有与缓冲器的顶表面接触的安装区域的载体。
    • 83. 发明授权
    • Online shopping system
    • 在线购物系统
    • US06336100B1
    • 2002-01-01
    • US09015442
    • 1998-01-29
    • Koji Yamada
    • Koji Yamada
    • G06F1760
    • G06Q30/06G06Q30/0633G06Q30/0643
    • An online shopping system has a server, at least one virtual store provided on the server and a plurality of pieces of customers terminal equipment electrically connected to the server. Each customer's order for at least one commodity being sold by the virtual store is made by the terminal equipment to the server. At least a place where the commodity is kept temporarily such as a 24-hour opened convenience store is selected as a place where the commodity should be delivered when the order is made.
    • 在线购物系统具有服务器,在服务器上提供的至少一个虚拟商店和电连接到服务器的多个顾客终端设备。 由虚拟商店销售的至少一种商品的每个客户的订单由终端设备发送到服务器。 选择至少一个临时保存商品的地方,如24小时开放的便利店,作为在作出订单时应交付商品的地方。
    • 86. 发明授权
    • Tricyclic compounds having ACAT inhibiting activity
    • 具有ACAT抑制活性的三环化合物
    • US5679703A
    • 1997-10-21
    • US523843
    • 1995-09-07
    • Masashi YanaseToshiaki KumazawaShiro ShirakuraEiko OishiKoji Yamada
    • Masashi YanaseToshiaki KumazawaShiro ShirakuraEiko OishiKoji Yamada
    • C07C275/28C07D313/12A61K31/335A61K31/38C07D337/12
    • C07C275/28C07D313/12C07C2103/32
    • Disclosed is a tricyclic compound represented by formula (I): ##STR1## where X.sup.1 -X.sup.2 represents CH.dbd.CH--CH.dbd.CH, CH.dbd.CH--CH.dbd.N or S--CH.dbd.CH; Y--Z represents CH.sub.2 --O or CH.sub.2 --S; then L--M represents C.dbd.CR.sup.9 (in which R.sup.9 represents hydrogen or lower alkyl) or CH--CR.sup.10 R.sup.11 (in which each of R.sup.10 and R.sup.11 independently represents hydrogen or lower alkyl); W represents NR.sup.4 (in which R.sup.4 represents hydrogen or lower alkyl) or O; each of R.sup.1, R.sup.2 and R.sup.3 independently represents hydrogen, lower alkyl, lower alkoxy, halogen, nitro, amino or mono or di-lower alkyl-substituted amino; R.sup.5 represents hydrogen or lower alkyl; each of R.sup.6, R.sup.7 and R.sup.8 independently represents hydrogen, halogen, lower alkyl or lower alkoxy; provided that when Y--Z represents CH.dbd.CH or CH.sub.2 CH.sub.2, then L--M represents C.dbd.CR.sup.9 (in which R.sup.9 has the same meaning as defined above),or CH--CR.sup.10a R.sup.11a (in which each of R.sup.10a and R.sup.11a represents lower alkyl of R.sup.10 and R.sup.11); and a pharmaceutically acceptable salt thereto. The compound and its salt have an ACAT inhibiting activity and are expected to have preventive and therapeutic effects on hyperlipemia and arteriosclerosis.
    • 公开了由式(I)表示的三环化合物:其中X 1 -X 2表示CH = CH-CH = CH,CH = CH-CH = N或S-CH = CH; Y-Z表示CH 2 -O或CH 2 -S; 那么L-M表示C = CR9(其中R9表示氢或低级烷基)或CH-CR10R11(其中R10和R11各自独立地表示氢或低级烷基); W表示NR4(其中R4表示氢或低级烷基)或O; R 1,R 2和R 3各自独立地表示氢,低级烷基,低级烷氧基,卤素,硝基,氨基或单或二低级烷基取代的氨基; R5代表氢或低级烷基; R 6,R 7和R 8各自独立地表示氢,卤素,低级烷基或低级烷氧基; 条件是当YZ表示CH = CH或CH 2 CH 2时,LM表示C = CR 9(其中R9具有与上述相同的含义)或CH-CR10aR11a(其中R10a和R11a各自表示R10和R11的低级烷基) ; 和其药学上可接受的盐。 该化合物及其盐具有ACAT抑制活性,预期对高脂血症和动脉硬化具有预防和治疗作用。
    • 89. 发明授权
    • Aminoalkylpyrrolidinylthiocarbapenem derivatives
    • 氨基烷基吡咯烷基硫代碳青霉烯衍生物
    • US5550121A
    • 1996-08-27
    • US312619
    • 1994-09-27
    • Susumu NakagawaShinji KatoSatoshi MuraseOsamu OkamotoRyuji MitomoKatsumi YamamotoKoji YamadaHiroshi Fukatsu
    • Susumu NakagawaShinji KatoSatoshi MuraseOsamu OkamotoRyuji MitomoKatsumi YamamotoKoji YamadaHiroshi Fukatsu
    • C07D207/12C07D477/20C07D487/04A61K31/40
    • C07D477/20C07D207/12
    • A compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or a methyl group, R.sup.2 is a hydrogen atom or a negative charge, R.sup.3 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkoxy group, a lower alkanoyloxy group, an amino group, an N-lower alkylamino group, an N,N-di-lower alkylamino group, a lower alkanoylamino group, an aroylamino group, a (lower alkylsulfonyl)amino group, a sulfamoylamino group, a cyano group, a nitro group, a group of --COOR.sup.4 (wherein R.sup.4 is a hydrogen atom or a lower alkyl group) or a group of --CON(R.sup.5)R.sup.6 (wherein each of R.sup.5 and R.sup.6 which may be the same or different, is a hydrogen atom or a lower alkyl group, or R.sup.5 and R.sup.6 form together with the adjacent nitrogen atom a heterocyclic group selected from the group consisting of an aziridinyl group, an azetidinyl group, a pyrrolidinyl group, a piperidyl group, a piperazinyl group, a 4-lower alkyl piperazinyl group and a morpholino group), A is a linear or branched lower alkylene group, X is a group of --N(R.sup.7)R.sup.8 (wherein each of R.sup.7 and R.sup.8 which may be the same or different, is a hydrogen atom or a lower alkyl group) or a group of --N.sup.+ (R.sup.9)(R.sup.10)R.sup.11 (wherein each of R.sup.9, R.sup.10 and R.sup.11 which may be the same or different, is a lower alkyl group), provided that when A is a linear lower alkylene group, R.sup.3 is other than a hydrogen atom; or a pharmaceutically acceptable salt or ester thereof.
    • 下式的化合物:其中R1是氢原子或甲基,R2是氢原子或负电荷,R3是氢原子,卤素原子,羟基,低级烷氧基 低级烷酰氧基,氨基,N-低级烷基氨基,N,N-二低级烷基氨基,低级烷酰基氨基,芳酰氨基,(低级烷基磺酰基)氨基,氨磺酰氨基, 氰基,硝基,-COOR 4(其中R 4是氢原子或低级烷基)或-CON(R 5)R 6(其中R 5和R 6可以相同或不同)的基团 是氢原子或低级烷基,或者R 5和R 6与相邻的氮原子一起形成选自氮丙啶基,氮杂环丁烷基,吡咯烷基,哌啶基,哌嗪基的杂环基 ,4-低级烷基哌嗪基和吗啉代基),A为直链或支链低级亚烷基,X为杂环 -N(R 7)R 8(其中可以相同或不同的R7和R8各自为氢原子或低级烷基)或-N +(R 9)(R 10)R 11(其中每个 R 9,R 10和R 11可以相同或不同,为低级烷基),条件是当A为直链低级亚烷基时,R 3不是氢原子; 或其药学上可接受的盐或酯。